I agree that ph 2 & 3 will tell the story however if the covid ph 2 is compelling I think there is the potential for RVX to be taken out at that point. Lots of biotech assets are aquired post ph 2. With compelling covid ph 2 and the strong BoM numbers when heart failure replaces stroke, RVX might make a BP jump. Often times however with those earlier ph acquisitions the CEO of the biotech is very proactive. The latest example of that that comes to my mind is Pfizer's acquisition of Trillium (ph 2), Jan Skvarka initiated the sale process. Time will tell...